SIGN UP FOR THE LIFEMAG BRIEF

Receive our top articles each week direct to your inbox

In the News

Puma's once-vaunted cancer drug dogged by side effects in Phase II results

Published on 13th Dec 2015

Published on 13th December 2015

Puma Biotechnology's ($PBYI) in-development breast cancer treatment demonstrated some clinical benefit in a Phase II trial, but the high rates of serious diarrhea that have long plagued the drug again resurfaced, clouding the therapy's regulatory future. 

Read more @ Fierce Biotech